Long non-coding RNA CRNDE is involved in resistance to EGFR tyrosine kinase inhibitor in EGFR-mutant lung cancer via eIF4A3/MUC1/EGFR signaling
S Takahashi, R Noro, M Seike, C Zeng… - International journal of …, 2021 - mdpi.com
(1) Background: Acquired resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) is an intractable problem for many clinical oncologists. The …
inhibitors (EGFR-TKIs) is an intractable problem for many clinical oncologists. The …
Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer
P Ma, M Zhang, F Nie, Z Huang, J He, W Li… - Biomedicine & …, 2017 - Elsevier
The non–small cell lung cancer (NSCLC) patients harbor mutations in the epidermal growth
factor receptor (EGFR) can be therapeutically targeted by EGFR tyrosine kinase inhibitors …
factor receptor (EGFR) can be therapeutically targeted by EGFR tyrosine kinase inhibitors …
Analysis of the lncRNA–miRNA–mRNA network reveals a potential regulatory mechanism of EGFR-TKI resistance in NSCLC
D Ding, J Zhang, Z Luo, H Wu, Z Lin, W Liang… - Frontiers in …, 2022 - frontiersin.org
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are widely used for
patients with EGFR-mutated lung cancer. Despite its initial therapeutic efficacy, most patients …
patients with EGFR-mutated lung cancer. Despite its initial therapeutic efficacy, most patients …
Genome-wide profiling of long non-coding RNA expression patterns in the EGFR-TKI resistance of lung adenocarcinoma by microarray
Y Wu, DD Yu, Y Hu, D Yan, X Chen… - Oncology …, 2016 - spandidos-publications.com
Mutations in the epidermal growth factor receptor (EGFR) make lung adenocarcinoma cells
sensitive to EGFR tyrosine kinase inhibitors (TKIs). Long-term cancer therapy may cause the …
sensitive to EGFR tyrosine kinase inhibitors (TKIs). Long-term cancer therapy may cause the …
Highly expressed long non‐coding RNA CRNDE promotes cell proliferation through PI3K/AKT signalling in non‐small cell lung carcinoma
XX Liu, HP Xiong, JS Huang, K Qi… - Clinical and …, 2017 - Wiley Online Library
Recently, numerous studies have revealed that long non‐coding RNAs (lncRNAs) play
complex roles in various lung diseases, while the colorectal neoplasia differentially …
complex roles in various lung diseases, while the colorectal neoplasia differentially …
Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer
N Cheng, X Li, C Zhao, S Ren, X Chen… - Oncology …, 2015 - spandidos-publications.com
The application of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
is limited by drug resistance in non-small cell lung cancer (NSCLC). Long non-coding RNAs …
is limited by drug resistance in non-small cell lung cancer (NSCLC). Long non-coding RNAs …
[HTML][HTML] Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT …
H Pan, T Jiang, N Cheng, Q Wang, S Ren, X Li… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Our previous study demonstrated that long non-coding RNA (lncRNA) BC087858 could
stimulate acquired resistance to EGFR-TKIs in non-small cell lung (NSCLC) but the specific …
stimulate acquired resistance to EGFR-TKIs in non-small cell lung (NSCLC) but the specific …
Emerging role of noncoding RNAs in EGFR TKI-resistant lung cancer
J Li, P Li, J Shao, S Liang, Y Wan, Q Zhang, C Li, Y Li… - Cancers, 2022 - mdpi.com
Simple Summary The introduction of epidermal growth factor receptor (EGFR)-tyrosine
kinase inhibitors (TKIs) has revolutionized the treatment of lung cancer. Nevertheless, TKI …
kinase inhibitors (TKIs) has revolutionized the treatment of lung cancer. Nevertheless, TKI …
LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis in lung …
J Wu, C Zheng, Y Wang, Z Yang, C Li, W Fang, Y Jin… - Biomarker …, 2021 - Springer
Background Epidermal growth factor receptor-tyrosinase kinase inhibitor (EGFR-TKI)
resistance is the major obstacle in the treatment of lung adenocarcinoma (LUAD) patients …
resistance is the major obstacle in the treatment of lung adenocarcinoma (LUAD) patients …
miR-146b-5p enhances the sensitivity of NSCLC to EGFR tyrosine kinase inhibitors by regulating the IRAK1/NF-κB pathway
YN Liu, MF Tsai, SG Wu, TH Chang, TH Tsai… - … Therapy-Nucleic Acids, 2020 - cell.com
Although patients with non-small cell lung cancer harboring activating mutations in the
epidermal growth factor receptor (EGFR) show good clinical response to EGFR tyrosine …
epidermal growth factor receptor (EGFR) show good clinical response to EGFR tyrosine …